BridgeMD
morPHinE clearance and glomerular filtration in the Drepanocytic in crisis in REAnimation.
EU CTIS ID: 2024-511985-34-00
What this study is testing
The main aim of our study is to identify a glomerular filtration threshold (CKD-Epi) predictive of failure of usual-dose morphine in sickle cell patients in vaso-occlusive crisis, to determine the population that would benefit from higher upfront morphine doses (personalized analgesia).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient ≥ 18 years
- Known homozygous sickle cell disease SS, SC, S-beta+ or S-beta0
- Admitted to a Continuous Care Unit (CCU) or intensive care unit.
- Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome
- Receiving morphine PCA therapy
- Obtained consent to participate in the study and/or from a parent/relative in the event of patient incapacity
You likely can't join if
- Patient included in the study during a previous stay
- Injection of iodinated contrast medium outside the study in the 24 hours prior to inclusion, or scheduled within 9 hours of the scheduled time of iohexol injection.
- Contraindication to iohexol: known or suspected immediate or delayed hypersensitivitý, thyrotoxicosis
- Patient on morphine therapy or methadone- or buprenorphine-type substitution therapy, prior to hospitalization (having received morphine or derivative by any route in the week preceding hospitalization)
- Chronic liver disease likely to interfere with morphine metabolism (cirrhosis stage)
- Patient under legal protection
See the full eligibility criteria
- Patient ≥ 18 years
- Known homozygous sickle cell disease SS, SC, S-beta+ or S-beta0
- Admitted to a Continuous Care Unit (CCU) or intensive care unit.
- Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome
- Receiving morphine PCA therapy
- Obtained consent to participate in the study and/or from a parent/relative in the event of patient incapacity
- Affiliation with a social securitý scheme.
- Patient included in the study during a previous stay
- Injection of iodinated contrast medium outside the study in the 24 hours prior to inclusion, or scheduled within 9 hours of the scheduled time of iohexol injection.
- Contraindication to iohexol: known or suspected immediate or delayed hypersensitivitý, thyrotoxicosis
- Patient on morphine therapy or methadone- or buprenorphine-type substitution therapy, prior to hospitalization (having received morphine or derivative by any route in the week preceding hospitalization)
- Chronic liver disease likely to interfere with morphine metabolism (cirrhosis stage)
- Patient under legal protection
- Pregnant or breast-feeding woman
- Any condition constituting a contraindication to the use of morphine according to the summary of product characteristics
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.